Mastodon

Derinat® (Solution) Instructions for Use

ATC Code

L03AX (Other immunostimulants)

Active Substance

Sodium desoxyribonucleate

Clinical-Pharmacological Group

Immunomodulator

Pharmacotherapeutic Group

Immunostimulants; other immunostimulants

Pharmacological Action

An immunomodulator affecting cellular and humoral immunity. The immunomodulatory effect of Derinat® is due to the stimulation of B-lymphocytes and activation of T-helpers.

Derinat® activates the nonspecific resistance of the body, optimizing inflammatory responses and the immune response to bacterial, viral, and fungal antigens. Derinat® stimulates reparative and regenerative processes.

It increases the body’s resistance to infections. It regulates hematopoiesis (normalizing the number of leukocytes, lymphocytes, granulocytes, phagocytes, platelets). Possessing pronounced lymphotropism, Derinat® stimulates the drainage-detoxification function of the lymphatic system.

Derinat® significantly reduces cell sensitivity to the damaging effects of chemotherapeutic drugs and radiation therapy.

Pharmacokinetics

Absorption and Distribution

It is rapidly absorbed from the injection site after intramuscular administration and distributed via lymphatic pathways to organs and tissues.

Sodium desoxyribonucleate has high tropism to hematopoietic organs, actively participates in cellular metabolism, integrating into cellular structures. It accumulates maximally in the bone marrow, lymph nodes, thymus, spleen, and to a lesser extent in the liver, brain, stomach, small and large intestine.

During the phase of intensive drug entry into the blood, redistribution occurs between plasma and blood cells, parallel with metabolism and excretion.

After a single injection, all pharmacokinetic curves describing the change in drug concentration in the studied organs and tissues are characterized by a rapid phase of increase and a rapid phase of decrease in concentration within the interval of 5-24 hours.

After intramuscular administration, Cmax is reached after 5 hours. The drug penetrates the blood-brain barrier. Cmax of the drug in the brain is reached after 30 minutes.

Metabolism and Excretion

Sodium desoxyribonucleate is metabolized in the body. It is excreted mainly by the kidneys and partially with feces. T1/2 after intramuscular administration is 72.3 hours.

Indications

  • Radiation injuries;
  • Impaired hematopoiesis;
  • Myelodepression and resistance to cytostatics in cancer patients, developed against the background of cytostatic and/or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapeutic drugs);
  • Stomatitis induced by cytostatic therapy;
  • Gastric and duodenal ulcer, erosive gastroduodenitis;
  • Coronary artery disease;
  • Obliterating diseases of the vessels of the lower extremities stages II-III;
  • Trophic ulcers, long-term non-healing wounds;
  • Odontogenic sepsis, purulent-septic complications;
  • Rheumatoid arthritis;
  • Burn disease;
  • Preoperative and postoperative periods (in surgical practice);
  • Chlamydia, ureaplasmosis, mycoplasmosis;
  • Endometritis, salpingo-oophoritis, endometriosis, fibroids;
  • Prostatitis, benign prostatic hyperplasia;
  • Chronic obstructive pulmonary diseases;
  • Pulmonary tuberculosis, inflammatory diseases of the respiratory tract.

ICD codes

ICD-10 code Indication
A15 Respiratory tuberculosis, bacteriologically and histologically confirmed
A40 Streptococcal sepsis
A41 Other sepsis
A56.0 Chlamydial infections of lower genitourinary tract
A56.1 Chlamydial infections of pelvic organs and other genitourinary organs
B96.0 Mycoplasma pneumoniae [M. pneumoniae] as the cause of diseases classified in other chapters
D25 Leiomyoma of uterus
D75.8 Other specified diseases of blood and blood-forming organs
I20 Angina pectoris
I73.0 Raynaud's syndrome
I73.1 Obliterative thromboangiitis [Buerger's disease]
I73.8 Other specified peripheral vascular diseases
I73.9 Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm)
I79.2 Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy)
I83.2 Varicose veins of lower extremities with ulcer and inflammation
J04 Acute laryngitis and tracheitis
J20 Acute bronchitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
J44 Other chronic obstructive pulmonary disease
K12 Stomatitis and related lesions
K25 Gastric ulcer
K26 Duodenal ulcer
K29 Gastritis and duodenitis
L89 Decubitus ulcer and pressure area
L98.4 Chronic skin ulcer, not elsewhere classified
M05 Seropositive rheumatoid arthritis
N40 Hyperplasia of prostate
N41 Inflammatory diseases of prostate
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N80 Endometriosis
T30 Burns and corrosions of unspecified body region
T66 Unspecified effects of radiation (radiation sickness)
Z98.8 Other specified postprocedural states
ICD-11 code Indication
1A81.0 Chlamydial infection of lower genitourinary tract
1A81.1 Chlamydial infection of internal reproductive organs
1B10.0 Respiratory tuberculosis, bacteriologically or histologically confirmed
1G40 Sepsis without septic shock
2B32.1 Reactive plasmacellular hyperplasia
2E86.0 Leiomyoma of uterus
3C0Z Diseases of the blood or blood-forming organs, unspecified
4A44.8 Thromboangiitis obliterans
8E61.0 Radiation-induced brain injury
8E61.1 Radiation-induced spinal cord injury
BA40.Z Angina pectoris, unspecified
BD42.0 Raynaud's disease
BD42.1 Raynaud's syndrome
BD42.Z Raynaud's phenomenon, unspecified
BD4Z Chronic obliterative arterial diseases, unspecified
BD53.Y Other specified secondary involvement of arteries and arterioles
BD5Z Diseases of arteries or arterioles, unspecified
BD74.Z Chronic venous insufficiency of lower extremities, unspecified
CA05 Acute laryngitis or tracheitis
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA22.Z Chronic obstructive pulmonary disease, unspecified
CA42.Z Acute bronchitis, unspecified
DA01.Z Diseases of the oral mucosa, unspecified
DA42.Z Gastritis, unspecified
DA51.Z Duodenitis, unspecified
DA60.Z Gastric ulcer, unspecified
DA63.Z Duodenal ulcer, unspecified
DA7Z Diseases of stomach or duodenum, unspecified
EA40 Tropical phagedenic ulcer
EF60 Ischemic ulceration of the skin
EG00 Dilation of skin vessels of the extremities
EH90.Z Pressure ulcer of unspecified degree
EM0Z Unspecified skin disorder
FA20.0 Seropositive rheumatoid arthritis
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA07.Z Salpingitis and oophoritis, unspecified
GA10.Z Endometriosis, unspecified
GA90 Hyperplasia of prostate
GA91.Z Inflammatory and other diseases of prostate, unspecified
MB40.7 Acroparesthesia
ME60.2 Ulcerative skin lesion of unspecified nature
NE11 Burn of unspecified body region
NF00 Exposure to radiation, not elsewhere classified
QB6Z Surgical or postprocedural conditions, unspecified
XN4NV Mycoplasma pneumoniae

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Solution

Derinat® in the form of a solution for topical and external use is prescribed depending on the localization of the pathological process.

The drug is prescribed to children from the first day of life and adults.

For the prevention of acute respiratory viral infections (ARVI), instill 2 drops into each nasal passage 2-4 times/day for 1-2 weeks. When symptoms of a respiratory disease appear, instill 2-3 drops into each nasal passage every 1-1.5 hours during the first day, then 2-3 drops into each nasal passage 3-4 times/day. The duration of the course of therapy is from 5 days to 1 month.

For inflammatory diseases of the nasal cavity and paranasal sinuses, instill 3-5 drops into each nasal passage 4-6 times/day; the duration of the course is 7-15 days.

For inflammatory diseases of the oral cavity, rinse the mouth with the drug solution 4-6 times/day (1 bottle for 2-3 rinses). The duration of the course of therapy is 5-10 days.

For chronic inflammatory diseases, fungal, bacterial and other infections in gynecological practice – intravaginal administration of tampons with the drug or irrigation of the vagina and cervix with 5 ml per procedure 1-2 times/day for 10-14 days.

For hemorrhoids, the drug is administered rectally using microenemas of 15-40 ml. The duration of the course of treatment is 4-10 days.

In ophthalmological practice for severe inflammatory and dystrophic processes, Derinat® is instilled into the eyes, 1-2 drops 2-3 times/day for 14-45 days.

For obliterating diseases of the lower extremities to achieve a systemic effect, instill 1-2 drops into each nasal passage 6 times/day, the duration of the course is up to 6 months.

For post-radiation necrosis of the skin and mucous membranes, for long-term non-healing wounds, burns, frostbite, trophic ulcers of various etiologies, gangrene, it is recommended to apply application dressings (gauze in 2 layers) with the drug applied 3-4 times/day or treat the affected surface with the drug from a sprayer 10-40 ml 4-5 times/day. The course of treatment is 1-3 months.

Adverse Reactions

Possibly, in patients with diabetes mellitus, a hypoglycemic effect is noted, which should be taken into account by monitoring blood glucose levels.

Contraindications

  • Hypersensitivity to the components of the drug.

Use in Pregnancy and Lactation

The patient should be warned that before using the drug during pregnancy and lactation, a doctor’s consultation is necessary. If it is necessary to prescribe the drug during pregnancy, the expected benefit for the mother and the potential risk to the fetus should be assessed.

Pediatric Use

For children, the frequency of intramuscular administration of the drug is the same as for adults. For children under 2 years of age, the drug is prescribed at an average single dose of 7.5 mg (0.5 ml of solution for intramuscular injection 15 mg/ml), for children aged 2 to 10 years, the single dose is determined at the rate of 0.5 ml of the drug per year of life. For children over 10 years of age, the average single dose is 75 mg (5 ml of solution for intramuscular injection 15 mg/ml), the course dose is up to 5 injections of the drug.

Special Precautions

The drug does not have embryotoxic, teratogenic, or carcinogenic effects.

Subcutaneous administration of the drug is possible.

The drug potentiates the therapeutic effect of basic therapy for gastric and duodenal ulcers.

Derinat® reduces the iatrogenicity of basic drugs in the treatment of rheumatoid arthritis, achieving 50% and 70% improvement according to a number of complex indicators of disease activity.

In surgical sepsis, the inclusion of Derinat® in complex therapy causes a decrease in the level of intoxication, activation of immunity, normalization of hematopoiesis, and improves the function of organs responsible for the processes of detoxification of the internal environment of the body (including lymph nodes, spleen).

According to recent clinical studies, the efficacy of Derinat® has been proven in patients with exacerbation of COPD of varying severity against the background of standard therapy. It is prescribed intramuscularly 5 ml of a 15 mg/ml solution every 24-48 hours, the course of treatment is 5-10 injections.

Overdose

No symptoms of overdose have been observed.

Drug Interactions

The use of Derinat® in complex therapy allows increasing the effectiveness and reducing the duration of therapy, with a significant reduction in the doses of antibiotics and antiviral agents and an increase in remission periods.

Derinat® increases the effectiveness of anthracycline antitumor antibiotics and cytostatics.

Storage Conditions

The drug should be stored out of the reach of children, protected from light, at a temperature not exceeding 25°C (77°F).

Shelf Life

The shelf life is 5 years.

Dispensing Status

The drug is dispensed by prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Pharmpak, LLC (Russia)

Manufactured By

Fz Immunnoleks, LLC (Russia)

Dosage Form

Bottle Rx Icon Derinat® Solution for intramuscular injection 15 mg/1 ml: fl. 5 ml 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection transparent, colorless.

1 ml 1 fl.
Sodium desoxyribonucleate 15 mg 75 mg

Excipients: sodium chloride – 45 mg, water for injection – up to 5 ml.

5 ml – glass bottles (5) – plastic contour packs (1) – cardboard packs.

Marketing Authorization Holder

Pharmpak, LLC (Russia)

Manufactured By

Fz Immunnoleks, LLC (Russia)

Dosage Form

Bottle OTC Icon Derinat® Solution for topical and external use 2.5 ml/1 ml: fl. or dropper bottle 10 ml 1 pc.

Dosage Form, Packaging, and Composition

Solution for topical and external use transparent, colorless, without foreign inclusions.

1 ml 1 fl. (10 ml)
Sodium desoxyribonucleate 2.5 mg 25 mg

Excipients: sodium chloride – 0.01 g, water for injection – up to 10 ml.

10 ml – glass bottles (1) – cardboard packs.
10 ml – glass bottles (1) with a spray nozzle – cardboard packs.
10 ml – glass dropper bottles (1) – cardboard packs.

Marketing Authorization Holder

Pharmpak, LLC (Russia)

Manufactured By

Fz Immunnoleks, LLC (Russia)

Dosage Form

Bottle Rx Icon Derinat® Solution for intramuscular injection 15 mg/1 ml: fl. 2 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection transparent, colorless, without foreign inclusions.

100 ml
Sodium desoxyribonucleate 1.5 g

Excipients: sodium chloride – 0.9 g, water for injection – up to 100 ml.

2 ml – bottles (10) – trays (1) – cardboard packs.

TABLE OF CONTENTS